News

According to the agreement, Elan will become an approximate 24% shareholder in Proteostasis. Elan will be eligible for licensing compounds that will be developed under the pact. As

Piperacillin and tazobactam for injection, the generic version of Zosyn, is indicated to treat patients with moderate to severe bacterial infections. Piperacillin is a penicillin antibiotic that fights

Under the agreement, the companies will jointly work for providing drug discovery platform to their existing and new clients to identify and develop new therapeutics targeting CNS disorder.

BAL30072, a novel siderophore (iron-binding) sulfactam antibiotic, was developed for the patients who were suffering from infections caused by multidrug-resistant Gram-negative bacteria. The Phase I study assessed the

Patanol is indicated for the treatment of the signs and symptoms of allergic conjunctivitis, including itching, redness, chemosis, tearing and lid swelling. The lawsuit was filed following Apotex’s

The results of the trial confirmed that as predicted, KP201 is cleaved in man, releasing the active pharmaceutical compound hydrocodone into the bloodstream at amounts equivalent to the

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. eMAX Health Systems

Originally, the licensing agreement was signed between BMS and AMRI in 2005. Under the agreement, AMRI has licensed BMS its technology around central nervous system (CNS) triple reuptake

The company expects to recruit around 900 patients suffering from moderate-to-severe blepharitis in a four-arm trial designed to evaluate both product candidates simultaneously. The efficacy and safety of